Company continues strategic expansion of industry-leading senior
CAMBRIDGE, Mass.–(BUSINESS WIRE)– Metamark Genetics, Inc. (“Metamark” or the “Company”), a leader in
commercializing high value urologic oncology products, announced today
that Peter Maimonis, Ph.D., has joined Metamark’s leadership team as
Senior Vice President and Chief Science Officer, effective October 7,
“With his accomplished background in the discovery and development of
oncology biomarkers, companion diagnostics, and assays, Peter Maimonis
will be a true asset to Metamark and our mission to make better patient
outcomes possible through access to better information,” said Kenneth
Weg, Metamark President and CEO. “We’re delighted to have Peter on board
to further advance Metamark’s lead product, ProMark®, as well
as continue to grow our comprehensive portfolio of meaningful diagnostic
Dr. Maimonis brings extensive experience in oncology research and
development, and specific proficiency in oncology biomarkers in the area
of prostate cancer. He has presented at a large number of national and
international scientific conferences, and published many peer-reviewed
articles and abstracts on cancer biomarkers. Dr. Maimonis has held
senior level positions in various areas of research and development at
Ciba-Corning, Chiron Diagnostics, Bayer Diagnostics, Decision
Biomarkers, and On-Q-ity, and most recently served as Vice President of
Biomarker Development at Biothera, working with their novel cancer
« Through advanced diagnostic technology and ProMark®,
its leading prognostic assay, Metamark delivers substantial value to
physicians and their patients facing prostate cancer, » stated Dr.
Maimonis. « I’m thrilled to join this world-class management and
scientific leadership team, and look forward to propelling Metamark’s
continued quest to effectively change patient outcomes and improve the
standard of care. »
Dr. Maimonis received his B.S. in Biology from MIT and his Ph.D. in
Tumor Immunology from Brown University, and subsequently received his
postdoctoral training at Dana Farber Cancer Institute in biomarkers for
lung and breast cancer. He was also a Research Fellow at Harvard with a
focus in assay development and clinical application through work with
clinicians and surgeons in the area of lung cancer.
Launched in late 2014,
ProMark® is the first proteomic classifier of biopsied
prostate tissue to assess whether an early-stage prostate tumor is
aggressive or indolent. Test results generated in Metamark’s Cambridge,
Mass. CLIA-certified laboratory can aid the decision to treat the cancer
aggressively or to choose a course of active surveillance.
Metamark Genetics, Inc. is
a privately-held biotechnology company founded to develop novel,
function-based prognostic and diagnostic tests aimed at improving cancer
care. The company’s proprietary genomic and proteomic discovery
platforms have led to significant discoveries in several disease areas,
including prostate, bladder, colon, and breast cancers. Through the
acquisition of HealthTronics Laboratory Solutions in 2013, Metamark has
become a leading provider of specialty urological pathology testing
services with the first fully integrated clinical model for the prostate
cancer care pathway.
For more information please visit the company’s website: www.metamarkgenetics.com.
Metamark® and ProMark® are registered trademarks
of Metamark Genetics, Inc.
Jerry Williamson, 617-583-1450
SVP & Chief
Feinstein Kean Healthcare
Source: Metamark Genetics, Inc.